Announced Sun, 9 Aug · 09:31 IST
Gland Pharma signs strategic CDMO deal with global pharma major
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+13.3%1-day move
₹2581.60
prior close
₹2632.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.2+0.4-0.1+0.2+13.3+11.6+14.9+14.9+12.4+9.9————
Up moveDown movePending
AI summary
Gland Pharma announced a strategic Manufacturing and Supply Agreement with an undisclosed leading global pharma company for technology transfer, manufacturing, and supply of sterile injectable products. Covers 55 SKUs across three sites including oncology and non-oncology products in vials, ampoules, and pre-filled syringes. Annualized revenue potential of USD 90-100 million once fully commercialized, with revenue starting from calendar year 2029 and tech transfer completing within two years.
Likely market impact
Positive long-term revenue visibility of USD 90-100 million, though revenue inflows begin only from 2029.